EXAS is likely to consolidate its recent gains.
A correction in the shares of the provider of Covid-19 tests appears to be over and a new uptrend is underway.
GDRX will not stay in a tight range for long.
I know that Trump's going to blunt our community mask initiative because who needs masks if it isn't a big deal if you are sick?
BMY's announced acquisition of MyoKardia for $13B comes less than a year after its purchase of Celgene.
An unyielding disdain for scientists permeates this administration. But if you listen to these professors the nation wouldn't be in this fix.
What does it all mean?
The charts and indicators of SGEN are looking healthy.
Neither candidate seems to be the enemy of the market -- at least not yet.
These names are displaying both technical and quantitative deterioration.